Wang Lao Ji drug enters phase III trials for acute pharyngitis

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited announced its subsidiary, Guangzhou Wang Lao Ji Pharmaceutical Co., Ltd., has officially initiated Phase III clinical trials for its Ke Gan Li Yan Oral Liquid. This drug is being tested for the treatment of acute pharyngitis (wind-heat syndrome).

Ke Gan Li Yan Oral Liquid, a proprietary product of Wang Lao Ji Pharmaceutical, received its new drug certificate and production approval in 1997. It is included in the 2025 edition of the Pharmacopoeia of the People's Republic of China. The company secured approval from the National Medical Products Administration in February 2024 to conduct these confirmatory clinical trials.

As of September 2025, approximately RMB18,154,200 in R&D expenses (unaudited) have been invested in this project. The company cautions investors about the inherent risks in pharmaceutical development, including long cycles and numerous stages that can be affected by uncertain factors.